|
|
BMS309403 |
| CAS No.: |
300657-03-8 |
| 分子式： |
C31H26N2O3 |
| 分子量： |
|
| 備注： |
中文名稱BMS309403中文同義詞2-[[2’-(5-乙基-3,4-二苯基-1H-吡唑-1-基)[1,1’-聯(lián)苯]-3-基]氧基]乙酸;2-(5-乙基-3,4-二苯基-吡唑-1-基)-聯(lián)苯-3-基氧基]乙酸;2’-(5-乙基-3,4-二苯基-吡唑-1-基)-雙苯基-3-氧基]乙酸;化合物BMS-309403;INHIBITOR|||BMS309403|||SELECTIVE|||BMS309403|||BMS-309403|||ORAL|||FATTYACID-BINDINGPROTEIN|||INHIBIT|||BMS-309403|||BMS309403|||ENDOTHELIAL|||UPTAKE|||GLUCOSE|||FABP|||BMS309403|||FUNCTION英文名稱2’’-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]ACETICACID英文同義詞2’’-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]ACETICACID;2-[[2’-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1’-biphenyl]-3-yl]oxy]-aceticacid;BMS309403;3-[2-(5-ETHYL-3,4-DIPHENYLPYRAZOL-1-YL)PHENYL]PHENOXYACETICACID;CS-495;BMS309403;BMS309403;Aceticacid,2-[[2’-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1’-biphenyl]-3-yl]oxy]-;2-[3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]phenoxy]aceticacidCAS號300657-03-8分子式C31H26N2O3分子量474.55EINECS號相關類別試劑;FABP4Inhibitor;selectiveinhibitorofadiChemicalbookpocyteFatty-Acid-BindingProtein(aFABP/aP2)Mol文件300657-03-8.mol結構式BMS309403性質(zhì)沸點657.5±55.0°C(Predicted)密度1.17儲存條件Sealedindry,RoomTemperature溶解度可溶于DMSO（高達至少25mg/ml）。形態(tài)白色粉末狀固體。酸度系數(shù)(pKa)3.15±0.10(Predicted)顏色灰白色或淺黃色穩(wěn)定性可在-20°下的DMSO中的溶液儲存長達1個月。BMS309403用途與合成方法生物活性BMS309403是FABP4小分子抑制劑，Kd值為4nM，對FABP4的選擇性比對FABP5和FABP3高100倍以上。靶點TargetValueFABP4(Cell-freeassay)4nM(Kd)體外研究TreatmentwithBMS-309403significantlydecreasedMCP-1productionfromTHP-1macrophagesinadose-andtime-dependentmanner.體內(nèi)研究BMS-309403sodium(15mg/kg;chronictreatment;dailyfor6weeks)improvesendothelialfunction,phosphorylatedandtotaleNOSandreducedplasmatriglyceridelevelsbutdidnotaffectendothelium-independentrelaxations.AnimalModel:C57BL/6Jmice(ApoE?/?mice)Dosage:15mg/kgAdministration:Chronictreatment;dailyfor6weeksResult:SignificantlyincreasedthephosphorylatedeNOS(Ser1177)andtotaleNOSbutnotthephosphorylatedtototaleNOSratioinaortaeof18weeksoldApoE?/?mice. |
| 結構式： |
 |
 |
|
聲明：以上信息未經(jīng)本網(wǎng)證實,僅供參考,華夏化工網(wǎng)不承擔任何風險責任. |
|
